Full Press Release Details
AI Raises up to $15 Million of Debt Financing and Strengthens Financial Position for U.S. Commercialization
Your publication date and time will appear here. | Source:
"This significant financing
provides Spectral AI with the resources necessary to finalize our commercialization efforts and bring our cutting- edge DeepView System
across the finish line to the U.S. market," said Dr. J. Michael DiMaio, M.D., Chairman of the Board of Directors of Spectral AI.
"We are excited to be working with Avenue Capital and expect the partnership to provide long-term benefits to the Company. This
supports our efforts to bring our technology to market and transform the way healthcare providers predict burn wound healing potential
and ultimately improve patient outcomes."
"We have been impressed with
the clinical data generated by Spectral AI's DeepView System and we believe it will offer significant benefits to burn victims in
the future," said Chad Norman, Senior Portfolio Manager at Avenue Capital Group.
Spectral AI, Inc. is a Dallas-based
predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications
involving patients with burns. The Company is working to revolutionize the management of wound care by "Seeing the Unknown "
with its DeepView System. The DeepView System is being developed as a predictive device to offer clinicians an objective and
immediate assessment of a burn wound's healing potential prior to treatment or other medical intervention. With algorithm-driven
results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and
accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about
the DeepView System, visit www.spectral-ai.com.
Certain statements made in this
release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United
States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategy, plans,
objectives, initiatives and financial outlook. When used in this press release, the words "estimates,"
"projected," "expects," "anticipates," "forecasts," "plans,"
"intends," "believes," "seeks," "may," "will," "should,"
"future," "propose" and variations of these words or similar expressions (or the negative versions of such
words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of
future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other
important factors, many of which are outside Company's control, that could cause actual results or outcomes to differ
materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any
forward-looking statements.
Investors should carefully consider
the foregoing factors, and the other risks and uncertainties described in the "Risk Factors" sections of the Company's
filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address
other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-
Media and Investor Relations, please contact:
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp Email: dk@atlcp.com
Intelligence Medical devices healthcare Medtech